Katherine E. Strathearn, Ph.D.
Affiliations: | 2010 | Medicinal Chemistry and Molecular Pharmacology | Purdue University, West Lafayette, IN, United States |
Area:
Parkinson’s disease, protein aggregationGoogle:
"Katherine Strathearn"Mean distance: 11.06
Parents
Sign in to add mentor| Jean-Christophe Rochet | grad student | 2010 | Purdue | |
| (Role of alpha-synuclein primary structure and oxidative stress in Parkinson's disease pathology.) | ||||
BETA: Related publications
See more...
Publications
|
You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect. |
| Tambe MA, de Rus Jacquet A, Strathearn KE, et al. (2023) Protective Effects of Polyphenol-Rich Extracts against Neurotoxicity Elicited by Paraquat or Rotenone in Cellular Models of Parkinson's Disease. Antioxidants (Basel, Switzerland). 12 |
| Tambe MA, de Rus Jacquet A, Strathearn KE, et al. (2023) Protective effects of polyphenol-rich extracts against neurotoxicity elicited by paraquat or rotenone in cellular models of Parkinson's disease. Biorxiv : the Preprint Server For Biology |
| Landeck N, Strathearn KE, Ysselstein D, et al. (2020) Two C-terminal sequence variations determine differential neurotoxicity between human and mouse α-synuclein. Molecular Neurodegeneration. 15: 49 |
| Ambaw A, Zheng L, Tambe MA, et al. (2018) Acrolein-mediated neuronal cell death and alpha-synuclein aggregation: Implications for Parkinson's disease. Molecular and Cellular Neurosciences. 88: 70-82 |
| Strathearn KE, Yousef GG, Grace MH, et al. (2014) Neuroprotective effects of anthocyanin- and proanthocyanidin-rich extracts in cellular models of Parkinson׳s disease. Brain Research. 1555: 60-77 |
| Dumitriu A, Pacheco CD, Wilk JB, et al. (2011) Cyclin-G-associated kinase modifies α-synuclein expression levels and toxicity in Parkinson's disease: results from the GenePD Study. Human Molecular Genetics. 20: 1478-87 |
| Su LJ, Auluck PK, Outeiro TF, et al. (2010) Compounds from an unbiased chemical screen reverse both ER-to-Golgi trafficking defects and mitochondrial dysfunction in Parkinson's disease models. Disease Models & Mechanisms. 3: 194-208 |
| Gitler AD, Chesi A, Geddie ML, et al. (2009) Alpha-synuclein is part of a diverse and highly conserved interaction network that includes PARK9 and manganese toxicity. Nature Genetics. 41: 308-15 |
| Gitler AD, Bevis BJ, Shorter J, et al. (2008) The Parkinson's disease protein alpha-synuclein disrupts cellular Rab homeostasis. Proceedings of the National Academy of Sciences of the United States of America. 105: 145-50 |
| Outeiro TF, Kontopoulos E, Altmann SM, et al. (2007) Sirtuin 2 inhibitors rescue alpha-synuclein-mediated toxicity in models of Parkinson's disease. Science (New York, N.Y.). 317: 516-9 |